Form 4: Taysha Gene Therapies Director John A. Stalfort III Reports Acquisition of Shares and Stock Options

Director John A. Stalfort III reports acquiring shares and stock options in Taysha Gene Therapies, Inc.

Summary

• On May 29, 2024, John A. Stalfort III, a director of Taysha Gene Therapies, Inc., reported acquiring 49,220 shares of common stock as a restricted stock unit (RSU) award.
• These RSUs will vest on the earlier of May 29, 2025, or the next annual stockholders meeting, contingent upon continued service as a director.
• Stalfort also acquired 98,440 stock options with an exercise price of $3.17, which also vest on the earlier of May 29, 2025, or the next annual stockholders meeting, with an expiration date of May 29, 2034.
• Following these transactions, Stalfort directly owns 98,440 derivative securities and 1,098,601 shares of common stock.
• Additionally, 884,290 shares are held indirectly by Gineane Holly Stalfort as Trustee of the John A. Stalfort III 2018 Irrevocable Trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and options by a director suggests confidence, but it's a routine filing and doesn't provide substantial new information about the company's performance.

Positives

• The acquisition of shares and stock options by a director could be interpreted as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• The reported transactions provide shareholders with insight into the director's stake in the company.

Key Dates